COVIDtests.gov – Free at-home COVID-19 tests
Every home in the U.S. is eligible to order 4 free at-home COVID-19 tests. The tests are completely free. Orders will usually ship in 7-12 days.
Every home in the U.S. is eligible to order 4 free at-home COVID-19 tests. The tests are completely free. Orders will usually ship in 7-12 days.
Background: Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatments on disparities…
Venous thromboembolism (VTE) is a common cause of morbidity and mortality. Although most patients can be managed safely with anticoagulation, inferior vena cava filters (IVCFs)…
Don’t miss what’s happeningPeople on X are the first to know.#tandem24 #bmtsm Hamilton: CD19 therapy drives clonal hematopoiesis and cytopenias. Looked at 69 non-relapsed LBCL CART…
Program: Oral and Poster Abstracts Type: Oral Session: 904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders…
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…
Program: Oral and Poster Abstracts Type: Oral Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment Hematology…
Program: General Sessions Session: Plenary Scientific Session Hematology Disease Topics & Pathways: Research, Fundamental Science, hematopoiesis, immunology, metabolism, Biological Processes, molecular biology, Metabolic Disorders, profiling,…
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…